We have located links that may give you full text access.
ENGLISH ABSTRACT
JOURNAL ARTICLE
REVIEW
[Biosimilars].
Therapeutische Umschau. Revue Thérapeutique 2011 November
Biosimilars are biological medicinal products referring to an existing biological originator product and submitted to regulatory authorities formarketing authorization by an independent applicant after the patent has expired. The European Medicines Agency (EMA) has issued overarching and specific guidelines that should be fulfilled in order to receive approval as biosimilar. In accordance with these guidelines biosimilars of recombinant somatropin, epoetin alfa, and granulocyte-colony stimulating factor have gained market authorisation in the EU. Similarity in terms of quality, safety and efficacy to a reference product was demonstrated. Points to consider when switching from the innovator product to a biosimilar, or from one biosimilar to another, are reported. INN-naming, labelling, pharmacovigilance issues, interchangeability, and substitution of biosimilars are still a matter of discussion.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app